BR112014010938A2 - compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico - Google Patents

compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico

Info

Publication number
BR112014010938A2
BR112014010938A2 BR112014010938A BR112014010938A BR112014010938A2 BR 112014010938 A2 BR112014010938 A2 BR 112014010938A2 BR 112014010938 A BR112014010938 A BR 112014010938A BR 112014010938 A BR112014010938 A BR 112014010938A BR 112014010938 A2 BR112014010938 A2 BR 112014010938A2
Authority
BR
Brazil
Prior art keywords
compounds
chk1
pyrazine
amino
present
Prior art date
Application number
BR112014010938A
Other languages
English (en)
Inventor
Collins Ian
Charles Reader John
Lainchbury Michael
Peter Matthews Thomas
Original Assignee
Cancer Res Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Tech Ltd filed Critical Cancer Res Tech Ltd
Publication of BR112014010938A2 publication Critical patent/BR112014010938A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico". a presente invenção refere-se geralmente ao campo de compostos terapêuticos. mais especificamente a presente invenção é relativa a certos compostos de piridil-amino-pirazina-carbonitrila que, inter alia, inibe a função de cinase de cinase 1 de ponto de checagem (chk1). a presente invenção também é relativa às composições farmacêuticas compreendendo tais compostos, e o uso de tais compostos e composições, tanto in vitro quanto in vivo, para inibir função de chk1 cinase, e no tratamento de doenças e condições que são mediadas por chk1, que são melhoradas pela inibição de função de chk1 cinase, etc., incluindo condições proliferativas tais como câncer, etc., opcionalmente em combinação com outro agente, por exemplo, (a) um inibidor de dna topoisomerase i ou ii; (b) um agente de dano de dna; (c) um inibidor de antimetabólito ou timidilato sintase (ts); (d) um agente alvejado por microtúbulo; e (e) radiação por ionização.
BR112014010938A 2011-11-09 2012-11-09 compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico BR112014010938A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557457P 2011-11-09 2011-11-09
PCT/GB2012/052786 WO2013068755A1 (en) 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
BR112014010938A2 true BR112014010938A2 (pt) 2017-05-16

Family

ID=47178213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010938A BR112014010938A2 (pt) 2011-11-09 2012-11-09 compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico

Country Status (10)

Country Link
US (3) US9040540B2 (pt)
EP (1) EP2776417B1 (pt)
JP (1) JP6073910B2 (pt)
CN (1) CN104105696B (pt)
AU (1) AU2012335409B2 (pt)
BR (1) BR112014010938A2 (pt)
CA (1) CA2849566C (pt)
ES (1) ES2709003T3 (pt)
RU (1) RU2641693C2 (pt)
WO (1) WO2013068755A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
CA2870837C (en) 2012-05-15 2022-05-10 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
CZ306322B6 (cs) 2014-12-17 2016-11-30 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP1435947B1 (en) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
WO2003101444A1 (en) 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP4758349B2 (ja) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US7326712B2 (en) 2003-10-14 2008-02-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
KR20080020602A (ko) 2005-04-28 2008-03-05 수퍼젠, 인크. 단백질 키나아제 저해제
AU2006264043B2 (en) 2005-06-28 2012-04-26 Sanofi-Aventis Isoquinoline derivatives as inhibitors of Rho-kinase
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101611012B (zh) 2006-12-27 2012-11-14 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹啉衍生物
CA2681015C (en) 2007-03-16 2016-06-21 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2725754C (en) * 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
CA2870837C (en) 2012-05-15 2022-05-10 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Also Published As

Publication number Publication date
CN104105696B (zh) 2017-11-14
US9040540B2 (en) 2015-05-26
ES2709003T3 (es) 2019-04-12
JP2014532751A (ja) 2014-12-08
AU2012335409B2 (en) 2017-07-13
RU2014121334A (ru) 2015-12-20
US9765059B2 (en) 2017-09-19
CN104105696A (zh) 2014-10-15
EP2776417B1 (en) 2018-10-31
EP2776417A1 (en) 2014-09-17
US20160304493A1 (en) 2016-10-20
CA2849566A1 (en) 2013-05-16
AU2012335409A1 (en) 2014-04-17
US20140315925A1 (en) 2014-10-23
US9403797B2 (en) 2016-08-02
WO2013068755A1 (en) 2013-05-16
RU2641693C2 (ru) 2018-01-22
JP6073910B2 (ja) 2017-02-01
US20150225372A1 (en) 2015-08-13
CA2849566C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
BR112014026801A2 (pt) 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazina-2-carbonitrila e usos terapêuticos do mesmo
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
BR112015022551A2 (pt) inibidores de amido pirrol
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112014010938A2 (pt) compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
MX2015010829A (es) Compuestos terapeuticos y sus usos.
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos
WO2013040227A3 (en) Therapeutic compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]